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Abstract.  Blood platelets have a  receptor for macro- 
molecular adhesive glycoproteins, located on a hetero- 
duplex membrane glycoprotein complex (GPIIb/IIIa) 
that only becomes "exposed" when platelets are acti- 
vated. Binding of the adhesive glycoproteins, in partic- 
ular fibrinogen, to the receptor is required for platelet 
aggregation, which in turn is required to arrest bleed- 
ing. A  murine monoclonal antibody whose rate of 
binding to the receptor is affected by platelet activation 
was both cross-linked and fragmented to assess the 
effects of changes in molecular size on its rate of bind- 
ing to unactivated and activated platelets. The results 
indicate that small molecules can bind more rapidly to 
the receptors on unactivated platelets than can large 
molecules and that activation involves a  conforma- 
tional and/or microenvironmental change that permits 
the large molecules to bind more rapidly. 
T 
HE activation response of human blood platelets rep- 
resents a remarkable evolutionary adaptation. Under 
normal conditions, platelets must circulate in isolation 
to avoid vascular occlusion; at sites of vascular injury, how- 
ever, they must aggregate one with another nearly instantane- 
ously in order to minimize hemorrhage. It is now clear that 
this is accomplished by a  mechanism wherein any one of 
several agonists (ADP, epinephrine, thrombin, collagen, or 
thromboxane A2) interacts with platelets so as to "expose" a 
receptor for fibrinogen; this receptor is only minimally ex- 
pressed or entirely cryptic on unactivated platelets (2).  The 
subsequent  binding  of  fibrinogen  to  platelets  correlates 
closely  with  aggregate  formation,  perhaps  because  the 
fibrinogen acts  as  a  bridging  molecule between platelets 
(fibrinogen has a bivalent structure and molecular dimen- 
sions  suitable  for  such  a  function),  although  additional 
post-fibrinogen binding steps may also be involved (20, 24). 
Compelling evidence exists that a calcium-dependent com- 
plex  made  up  of two  glycoproteins  (GPIIb,  a  2-chain, 
disulfide-bonded glycoprotein of Mr 143,000, and GPIIIa, a 
single-chain glycoprotein of Mr 88,000) is the site to which 
fibrinogen binds (2, 3,  15). In fact, recent data indicate that 
other high molecular weight adhesive glycoproteins (fibro- 
nectin, von Willebrand factor, and perhaps thrombospondin) 
may also bind to or near the GPIIb/IIIa complex upon appro- 
priate activation (13, 26,  28),  but the physiologic roles for 
these interactions remain to be clarified. At present, all plate- 
let aggregation induced by agonists present in vivo seems to 
rely on this receptor mechanism; thus, it occupies a crucial 
role in hemostasis and thrombosis. 
The mechanism by which the GPIIb/IIIa receptor becomes 
exposed is poorly understood.  Both glycoproteins can be 
labeled on unactivated platelets by membrane-impermeant 
probes and so they must be present on the surface of the 
platelets even when they cannot bind fibrinogen (3). Because 
the two glycoproteins are held together by calcium, it was 
proposed that the activation mechanism might involve in- 
creased availability of calcium and the joining together of the 
glycoproteins (15). However,  evidence derived from several 
different  immunologic and biochemical approaches indicates 
that GPIlb and GPIIIa probably exist as a complex even on 
unactivated platelets (5, 9,  15, 31). Thus, it can be inferred 
that the exposure mechanism must involve a change in the 
GPIIb/IIIa complex itself and/or its microenvironment. 
Studies to define the exposure mechanism have been ham- 
pered by the lack of a probe that can report on such a change 
in the receptor, and so they have been confined to what can 
be inferred from the binding of fibrinogen, its fragments, or 
the other ligands themselves. I recently reported a new mu- 
rine monoclonal antibody (designated 7E3) directed against 
the GPIIb/IIIa receptor whose rate of binding to platelets was 
significantly increased by activation with ADP or several 
other agonists. This increase indicated preferential or exclu- 
sive reactivity with the activated form of the complex (4). 
The availability of the antibody permitted the present study, 
which is designed to test the hypothesis that the exposure 
mechanism is size-selective; that is, fibrinogen and the other 
ligands are excluded or restricted from binding to unacti- 
vated receptors by virtue of their large size, and activation 
results in greater access of such large molecules to the bind- 
ing site on the receptor. I  reasoned that if this were true, 
smaller fragments (F[ab']2  and Fa~) of the 7E3  antibody 
might bind more rapidly to unactivated platelets than the in- 
tact antibody and show less enhancement of their binding 
with platelet activation. Conversely, cross-linked aggregates 
of the  intact  antibody  (dimers,  trimers,  and  tetramers), 
which approach  the molecular dimensions of fibrinogen, 
would be expected to bind less rapidly than the intact anti- 
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crease in binding rate with activation. 
Materials and Methods 
Purification and Iodination of 7E3 and Its Fragments 
Intact antibody 7E3 was purified from ascites fluid by ion-exchange chro- 
matography  (DE-52;  Whatman  Chemical  Separation Inc.,  Clifton,  NJ) 
using a linear gradient from 0-0.15 M NaC1 in 5 mM Tris/Cl. It was then 
either further purified by affinity chromatography on protein A-agarose 
(Boehringer Mannheim Diagnostics, Houston, TX) and iodinated with io- 
dogen (Pierce Chemical Co., Rockford, IL; 25 ~tg coated on a glass scintil- 
lation vial in dichloromethane; 0.26 mg protein in  1 nil;  1 mCi  ~25I; 10 
min; 22°C) or fragmented into F(ab')2  with pepsin (2%  wt/wt pepsin A 
[Worthington Biochemical Co., Freehold, NJ] for 17 h at 37°C) and purified 
by chromatography on Sephacryl S-300 (Pharmacia Fine Chemicals, Pis- 
cataway,  NJ).  The F(ab')2  fragment was then iodinated and either used 
directly or after conversion into Fab' by reduction (50 mM 2-mercaptoeth- 
anol, 60 rain, 22°C) and alkylation (60 mM iodoacetamide [pH 8.3]  30 
min, 22°C).  Unlabeled, purified 7E3 and the three radiolabeled prepara- 
tions were denatured in SDS and electrophoresed in a 7% polyacrylamide 
gel as previously described (4).  Another IgGi monoclonal antibody pro- 
duced in our laboratory (6D1) that is directed against platelet glycoprotein 
Ib (5)  served as a control. It was purified, fragmented, and iodinated as 
above, with only minor variations. 
Cross-linking of 7E3 (30) 
Intact 7E3 antibody was purified by protein A-agarose affinity chromatogra- 
phy using the Bio-Rad MAPS buffer system (Bio-Rad Laboratories, Rich- 
mond, CA) and then dialyzed against 0.2 M Tris/Cl (pH 8.53).  The anti- 
body  was  then  concentrated to  57  mg/ml  (0.2  mi)  using  a  membrane 
filtration device (Centricon 30; Amicon Corp., Danvers, MA) that had been 
prerun with the 0.2 M Tris/CI buffer to remove residual glycerol. A fivefold 
molar excess of dimethyl suberimidate (8.8 Ixi of a freshly prepared, 40-raM 
stock solution in the same buffer) was then added and allowed to react for 
1 h at 22°C. The reaction was stopped by adding 0.8 mi of 0.2 M Tris/Cl, 
(pH 2.2) and placing the solution (final pH 7.3) on ice. The solution was 
then immediately applied to a  1 x  115-cm column of Sepharose 6B (Phar- 
macia Fine Chemicals) and eluted with 0.15 M NaCI, 0.01 M Tris/Cl, 0.05 % 
sodium azide (pH 7.4) at 2 ml/h. Polyacrylamide gel electrophoresis showed 
that the column had separated intact 7E3 from 7E3 dimers and a combina- 
tion of 7E3 trimers plus tetramers. 2 ml of the intact 7E3 was then digested 
with pepsin and a portion further reduced and alkylated as indicated above. 
The five different 7E3 preparations (FAN, F[ab']2,  intact 7E3, dimer, and 
trimer +  tetramer) were then iodinated with 125I using iodogen and elec- 
trophoresed in a 5.5%  SDS polyacrylamide gel; after drying, the gel was 
subjected to radioautography. 
Antibody Binding Studies 
Platelet-rich plasma (PRP) ~ (1.64-3.13  x  10 ~ platelets/liter) was prepared 
from whole human blood anticoagulated with 0.01-vol of 40%  sodium ci- 
trate. For the studies with intact antibody 7E3 and its fragments, 0.2 ml of 
the PRP was incubated for 30 s with either 22 I.tl of buffer (0.15 M NaCI, 
0.01 M Hepes [pH 7.4]) or 50 ~tM ADP in the same buffer (final concentra- 
tion 5  ~tM) and then aliquots of the radiolabeled antibody species were 
added to achieve final concentrations between 2.4 and 19 nM for each spe- 
cies. For studies with the cross-linked 7E3 and its fragments, PRP (3.22  × 
10 H platelets/liter) was treated with buffer or ADP as above and then the 
radioactive species were added (1-7.5 ~tl; 3.1 nM final concentration for each 
species assuming a Mr of 480,000  for the trimer plus tetramer), At the in- 
dicated time points, duplicate 0.1-ml samples were layered over 0.1 ml of 
30% sucrose, and platelet-bound antibody was separated from free antibody 
by centrifugation. The total active antibody concentration in each prepara- 
tion was estimated by incubating a trace amount of the antibody with an ex- 
cess of platelets for 1-2 h and determining the percentage bound (69-89% 
for the intact antibody and its fragments, and 81-93% for the cross-linked 
antibody and its fragments) (4). The binding rate was then calculated from 
the percentage of active antibody bound per minute per platelet, with nor- 
malization to 1 nM. Control experiments showed that nonspecific binding 
using an excess of intact 7E3 for each species was 0.5-3 % of  the total radio- 
1.  Abbreviation used in this paper:  PRP, platelet-rich plasma. 
activity, Equilibrium binding studies were performed as previously described 
(4) to determine the maximum number of 7E3 molecules of each species 
that could bind per platelet. 
Determination of  Apparent Stokes Radii 
The apparent Stokes radii of antibody 7E3 and its fragments were deter- 
mined by chromatography on a  111  x  l-cm column of Sephacryl S-200 
(Pharmacia Fine Chemicals) using a 0.5 M NaC1, 0.01 M Tris/C1,  0.05% 
sodium azide, pH 7.4 buffer, and a flow rate of 2 ml/h. The void volume 
was determined with blue dextran and the column was calibrated with cata- 
lase (52.2  /~),  aldolase (48.1 /~), bovine serum albumin (BSA)  (35.5/~), 
ovalbumin (30.5  /~),  chymotrypsinogen A  (20.9  A), and ribonuclease A 
(16.4/~) as recommended by the manufacturer (gel filtration calibration kit; 
Pharmacia Fine Chemicals) by plotting the ~/-s]-6g(~v) vs. the apparent 
Stokes radius. Radiolabeled 7E3 and its fragments were chromatographed 
twice, once with the standard protein with the closest Mr and then, for 
confirmation, with the standard proteins that appeared to elute just before 
and just after the 7E3 species being tested. In each case, the repeat chro- 
matogram confirmed the relative elution position of the 7E3 species. 
The apparent Stokes radii of the cross-linked 7E3  species (dimer and 
trimer plus tetramer) and fibrinogen (Cutter Laboratories, Berkeley,  CA) 
were determined on a 115 x  1 cm column of Sepharose 6B (Pharmacia Fine 
Chemicals) using a 0.15 M NaC1, 0.01 M Tris/Cl, 0.05 % azide, pH 7,4 buffer 
with a flow rate of 2 ml/h. The column was calibrated with thyroglobulin 
(85.0/~),  ferritin (61.0 .~),  catalase, and aldolase as described above (gel 
filtration calibration kit; Pharmacia Fine Chemicals) and then fibrinogen 
and the 7E3 species were tested. Since the observed value for fibrinogen 
(79.5 /~) was considerably below the 107-110 A predicted by its diffusion 
coefficient (17, 22), 125I-labeled fibrinogen (a gift of Dr. Ellinor Peerschke, 
State  University of New  York  at  Stony Brook,  Stony Brook,  NY)  and 
thyroglobulin were chromatographed together; this confirmed that fibrino- 
gen  eluted  later  than  thyroglobulin.  A  similar  difference between the 
predicted and observed Stokes radii for fibrinogen has been found in previ- 
ous studies (17, 22) and one conceptual model advanced to explain this is 
that under certain circumstances asymmetric molecules may preferentially 
enter gel pores "end-on  ~ (22). Since the 7E3 trimer plus tetramer has a Mr 
greater than fibrinogen, I decided to confirm its elution after fibrinogen by 
chromatographing a  mixture of fibrinogen and  radiolabeled trimer plus 
tetramer; the latter again eluted later than the former, reflecting fibrinogen's 
greater asymmetry. 
Immunoelectrophoresis of the radiolabeled antibody species was per- 
formed as previously described (4). After electrophoresis, the arcs were de- 
veloped with rabbit anti-mouse IgG (Sigma Chemical Co., St. Louis, MO). 
The intact antibody and the dimethyl suberimidate-treated dimeric and tri- 
meric plus tetrameric antibody all had the same mobility, which was some- 
what anodal  to the insertion well.  The  F(ab')2  and Fab' fragments both 
migrated to the same position, which was somewhat less anodal than the 
other species, but still anodal to the insertion well. 
Results 
7E3 and its F(ab')2 and Fab' fragments were purified and ra- 
diolabeled (Fig.  1). Fig. 2  shows  the binding of intact 7E3 
and  its  fragments to platelets  in PRP  ('~1.8  ×  1011 plate- 
lets/liter) as a function of time. The rates were nearly linear 
over the first minute and then decreased to 79  +  1% (mean 
+  SD) of the 1-min value at 2 min. The percentage of added 
antibody that was bound at 1 min ranged from '~7% for the 
intact antibody without ADP to "~20% for the F(ab'h frag- 
ment with ADP, indicating that the free antibody concentra- 
tion was not limiting at the early time points. The binding 
rate to unactivated platelets was lowest with the intact anti- 
body, intermediate with the F(ab')2  fragment, and greatest 
with the Fab' fragment. Pretreatment of platelets with ADP 
increased the rate of binding of the intact antibody most, had 
an intermediate effect on the F(ab'h fragment, and had the 
least effect on the binding of the Fab' fragment. 
Table I gives the results from another series of experiments 
performed with a different preparation of 7E3 and its frag- 
ments,  in which three different concentrations of antibody 
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antibody  7E3  and  its  frag- 
ments.  Lane A, a Coomassie 
Blue  stain of the  intact 7E3. 
Lanes B-D;  radioautographs 
of Fab' 7E3, F(ab')2 7E3, and 
intact  7E3.  The Fab' has  an 
Mr of ~25 kD rather than 50 
kD because the two ~25-kD 
chains  are  held  together  by 
noncovalent  interactions  that 
are disrupted  by SDS. 
were used, the platelet count was ~3.0 ×  10 l~ platelets/liter, 
and the binding rates were derived from a  1-min incubation. 
The binding rates for the intact antibody and its fragments 
were essentially  constant over the  range of concentrations 
tested  (2.4-19  nM)  with  even the  fastest binding  sample, 
(Fab')2  fragment binding to ADP-treated platelets,  showing 
only a  10 % difference. At the lowest concentration of anti- 
body, the fraction of platelet GPIIb/IIIa  molecules occupied 
by antibody at 1 min ranged from 1.1% for the intact antibody 
without  ADP to  3.5%  for the  F(ab')2  fragment with ADP, 
indicating that the concentration of free GPWo/IIIa molecules 
was  not  limiting.  As  in  the  studies  shown  in  Fig.  2,  the 
smaller fragments bound significantly more rapidly to unac- 
tivated platelets than did the intact antibody; the Fab'2 frag- 
ment bound 63 % faster than theintact antibody and the Fab' 
fragment bound 83 % faster than the intact antibody. When 
platelets were preactivated with ADP, antibody binding rate 
increased  at  all  concentrations,  with  the  intact  antibody 
demonstrating the greatest increase in binding rate (166%), 
the Fab'2 fragment having an intermediate increase (98 %), 
and the Fab' having the least (36%). The binding rates of the 
three species to ADP-activated platelets were also compared 
with each other; unlike the progressive increase in binding 
rates with smaller species that was observed with unactivated 
platelets, the intact antibody and Fab' fragment had similar 
rates, whereas the binding rate of the F(ab')2 fragment was 
~25%  greater.  Equilibrium-binding  studies  on  the  same 
samples  showed  that  activation  with  ADP  did  not 
significantly  alter  the  maximum number  of molecules  of 
each species that could bind per platelet, but the number of 
Fab' molecules bound to both unactivated and activated plate- 
lets  consistently  exceeded  the  number  of  intact  7E3  or 
F(ab')2 molecules (Table II). This latter observation may be 
due to steric factors and/or the valence difference between 
the species. 
Since the smaller fragments differ from the intact antibody 
in diffusion rate in addition  to size,  and the  Fab' fragment 
differs from the intact antibody and the F(ab')2 fragment in 
valence, control studies were performed with antibody 6D1, 
which reacts with GPIb. In one of three similar studies per- 
formed  at  1  nM  antibody  using  a  30-s  time  point,  the 
F(ab')2 fragment of 6D1  bound  19%  more rapidly than the 
intact antibody (1,989 vs. 1,665 molecules/platelet/min/nM), 
whereas the Fab' fragment's rate (1,839) was less than that of 
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Figure 2. Time course of binding 
of intact 7E3 and 7E3 fragments 
to unactivated and activated plate- 
lets.  PRP (0.2 ml; 1.64-1.89  × 
10 H platelets/liter) was incubated 
with buffer or ADP for 30 s and 
then 1 ¢.tl of radiolabeled antibody 
(16 nM  final  concentration  for 
all species) was added.  Platelet- 
bound  antibody  was  separated 
from free antibody at the indicat- 
ed  times.  The  points  represent 
the means of four different exper- 
iments  performed  in  duplicate. 
The bars are  +  1 SEM. 
Rate of Binding of 7E3 and Its Fragments (molecules per platelet per minute per nanomolar) 
Intact 7E3  F(ab')27E3  Fab'7E3 
Concentration  -ADP  +ADP  -ADP  +ADP  -ADP  +ADP 
nm 
2.4  ±  0.5  199"  540  317  705  375  517 
6.6  ±  1  209  546  375  662  381  511 
19.0  211  569  319  634  383  515 
207  ±  6~  551  ±  12(166%)  337  ±  14  666  ±  13(98%)  379  ±  6  515  ±  8(36%) 
PRP (3.05-3.13  ×  10 H platelets/liter) was incubated with buffer or ADP for 30 s and then 22.4 p,I of radiolabeled antibody was added to achieve three different 
final concentrations for each species (2.4  +  0,5, 6.6  +  1.0, and 19 riM). After 1 min, free antibody was separated from bound antibody. Similar data were obtained 
in four other experiments, and two other preparations of 7E3 and its fragments gave similar results. 
* Mean of three separate experiments. 
~t Mean  +  SEM was obtained by pooling all the data from the three different experiments conducted at three different antibody concentrations. The numbers in 
parentheses are the percentage increases in binding rates with activated platelets compared with unactivated platelets. 
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to Platelets 
-ADP  +ADP 
7E3  45,700  +  1,100*  38,200  +  5,400 
F(ab')2  45,500  +  3,400  49,100  +  2,100 
Fab'  75,400  +  4,900  93,200  +  6,100 
Equilibrium-binding studies were performed on the three PRP samples report- 
ed in Table I  after adjustment to  10"  platelets/liter.  The numbers of Fab' 
molecules bound per platelet,  with or without ADP stimulation, were  sig- 
nificantly  different  from the  numbers of intact  7E3  and  F(ab')2  fragments 
bound per platelet (P < 0.02). Similar differences were observed in three other 
experiments. Differences between values for each of the species, with and 
without ADP stimulation, were not significant. 
* Mean +  SEM 
intact antibody. These data suggest that the F(alY)2 may bind 
more rapidly than the intact antibody due to an increase in 
diffusion rate (although it is possible that steric considera- 
tions may also be involved in access to GPIb), but that any 
additional advantage in diffusion rate enjoyed by the Fab' 
fragment is neutralized by the decrease in valence from two 
to one. The results with 6D1 are very similar to those ob- 
tained  when  7E3  bound  to  ADP-activated  platelets  (the 
F[ab']2 bound more rapidly than the intact antibody, but the 
Fab'  bound  less  rapidly  than  the  F[ab']2),  but  markedly 
different from those obtained when 7E3 bound to unactivated 
platelets.  (The F[alY]2 fragment of 7E3 bound 63%  faster 
than  the  intact antibody  whereas  the  F(alY)2 fragment of 
6D1 bound only 19 % faster. The Fab' fragment of 7E3 bound 
83 % faster than the intact antibody whereas the FalY frag- 
ment of 6D1 bound just 10% faster.) This suggests that a fac- 
tor(s) other than bulk diffusion rate and valence affects the 
binding of 7E3  and its fragments to unactivated platelets, 
whereas the differential binding rates of 7E3 and its frag- 
ments for activated platelets are consistent with the differ- 
ences in diffusion rates and valence among the species as 
judged by the data with 6D1. 
Fig. 3 shows the characterization and binding data on 7E3 
antibody  treated  with  the  cross-linking  agent  dimethyl 
suberimidate (30). In accord with the proposed hypothesis, 
the dimeric and trimeric plus tetrameric species bound less 
rapidly than the intact antibody to unactivated platelets and 
showed the greatest increment in binding rate with activa- 
tion. Apparent Stokes radii determinations showed that even 
the  7E3  trimer  plus  tetramer  had  a  smaller  radius  than 
fibrinogen  (Table III).  Fibrinogen,  in  fact,  does  show  a 
greater difference in binding rates to unactivated and acti- 
vated platelets  than  any of the  species  tested;  very little 
fibrinogen binds to unactivated platelets despite prolonged 
incubation  (2),  whereas  even  the  trimer  plus  tetramer 
showed a pattern of slow, but progressive binding with time. 
Discussion 
These data demonstrate that smaller Mr species of 7E3 bind 
more rapidly to unactivated platelets than do larger Mr spe- 
cies. In addition, the smaller species show less of an increase 
in binding rate when platelets are activated with ADP than 
do the larger ones.  Although there are many potential ex- 
planations for these data,  I believe the most consistent ex- 
planation is that there is only very limited access of large 
molecules  to  the  binding  site  on the  GPIIb/IIIa complex 
receptor on unactivated platelets and that platelet activation 
results in increased accessibility of ligands of large size to 
this  binding  site.  Although  the  antibody species differ in 
diffusion rate, valence, and charge, these differences cannot 
account for the differential binding behavior with unactivated 
and activated platelets. If the increased diffusion rate of the 
smaller species were the sole factor responsible for the ob- 
served increased rate of binding to unactivated platelets, then 
one would also expect these same differentials in binding 
rates with activated platelets, in which case the binding rate 
ratios for activated and unactivated platelets would be identi- 
cal for all of the species. The data in Table I and Figs. 2 and 
3 show this is not the case, with Fig. 3 C graphically depict- 
ing a systematic change in the ratios of the rates. Additional 
evidence against differences in diffusion rate and/or valence 
explaining the binding behavior of 7E3 and its fragments to 
unactivated platelets comes from the studies showing that an- 
tibody 6D1  (directed against GPIb)  and its  fragments be- 
haved very differently from 7E3 with unactivated platelets, 
but very similarly to 7E3 with activated platelets. Moreover, 
changes in valence between the species would be more likely 
to operate to minimize the effects of size; thus, the increased 
valence of the cross-linked species would more likely in- 
crease, rather than decrease, their binding rates with unacti- 
vated platelets, and the decreased valence of the Fab' frag- 
ment would more likely decrease, rather than increase, its 
binding  rate  with  unactivated platelets.  Finally,  although 
there is a difference in charge between the F(ab')2 and Fab' 
fragments  on  the  one hand,  and  the  intact antibody,  the 
dimethyl suberimidate-treated dimeric antibody, and the tri- 
meric plus tetrameric antibody on the other hand, this cannot 
account for the pattern of differences observed within each 
group of identical charge. 
The recent demonstration that small peptides containing 
the amino acid sequence in the ?-chain of fibrinogen that is 
thought to be involved in binding to platelets bind equally 
well to unactivated and activated platelets (14), is also consis- 
tent with a model in which the GPIIb/IIIa exposure mecha- 
nism operates, at least in part, by modulating access on a 
size-dependent basis.  Similarly, preliminary evidence indi- 
cates that a  hepta-peptide containing the arginine-glycine- 
aspartic acid sequence that has been implicated in the bind- 
ing of fibronectin, von Willebrand factor, and the Act-chain 
of fibrinogen to platelets, also binds equally well to unacti- 
vated and activated platelets (16). Additional support comes 
from  the  discovery  that  an  IgM  monoclonal  antibody 
directed against GPIIb/I/Ia that is larger than any of the spe- 
cies tested in the current study, showed a greater discrimina- 
tion between unactivated and activated platelets than does 
Table IlL  Apparent Stokes Radii of Fibrinogen 
and Antibody  7E3 Species 
Fibrinogen  79.5 
7E3  Trimer plus tetramer  72.5 
7E3 Dimer  62.0 
7E3  40.9 
7E3 F(ab'h  33.5 
7E3 Fab'  23.9 
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the different species of 7E3 rather than a threshold phenome- 
non, there may be considerable variation in the accessibility 
of different  GPIIb/IIIa receptors.  This  is  consistent  with 
there being heterogeneity among these receptors. Moreover, 
since fibrinogen shows more of a  threshold  response than 
even the largest 7E3 aggregates, additional factors may oper- 
ate to prevent its interaction with unactivated platelets. 
Whether the ultimate control of the access of large mole- 
cules to the GPIIb/llla complex is mediated by a change in 
the receptor's conformation or its microenvironment remains 
to be determined. The observations that chymotrypsin diges- 
tion of platelets results in exposure of fibrinogen receptors 
even in  the  absence of agonist activation (18, 21)  and  that 
GPIIb/IIIa  extracted from platelets retains the ability to bind 
at least some fibrinogen (1,  12,  19,  23) might seem to favor 
a  model invoking a  microenvironmental change,  but addi- 
tional direct data are required before this model can be ac- 
cepted. Finally, there is reason to suspect that the interaction 
of adhesive glycoproteins with the platelet GPIIb/IIIa com- 
plex may have significance that transcends platelet physiol- 
ogy; hence, proteins immunologically related to GPHb and 
GPIIIa have been identified in endothelial cells (8,  33) and 
endothelial cells have been reported to bind fibrinogen (7). 
Moreover,  the  arginine-glycine-aspartic  acid  sequence, 
which has been implicated in the binding of adhesive glyco- 
proteins to platelets  (10, 11,  16,  27,  29)  and the binding of 
fibronectin to a variety of eukaryotic cells (25), is found in 
a substantial number of proteins that are involved in different 
cell adhesion phenomena (25). Additional studies will be re- 
quired to assess whether comparable activation-dependent 
changes in access are involved in the interactions between 
these other ceils and adhesive glycoproteins. 
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